ACAD
Price
$17.47
Change
+$0.54 (+3.19%)
Updated
May 9, 12:13 PM (EDT)
Capitalization
2.82B
82 days until earnings call
CTMX
Price
$1.01
Change
-$0.08 (-7.34%)
Updated
May 9, 12:45 PM (EDT)
Capitalization
77.44M
3 days until earnings call
Ad is loading...

ACAD vs CTMX

Header iconACAD vs CTMX Comparison
Open Charts ACAD vs CTMXBanner chart's image
ACADIA Pharmaceuticals
Price$17.47
Change+$0.54 (+3.19%)
Volume$475
Capitalization2.82B
CytomX Therapeutics
Price$1.01
Change-$0.08 (-7.34%)
Volume$28.65K
Capitalization77.44M
ACAD vs CTMX Comparison Chart
Loading...
ACAD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CTMX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ACAD vs. CTMX commentary
May 09, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACAD is a StrongBuy and CTMX is a Hold.

Ad is loading...
COMPARISON
Comparison
May 09, 2025
Stock price -- (ACAD: $16.93 vs. CTMX: $1.09)
Brand notoriety: ACAD and CTMX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ACAD: 293% vs. CTMX: 237%
Market capitalization -- ACAD: $2.82B vs. CTMX: $77.44M
ACAD [@Biotechnology] is valued at $2.82B. CTMX’s [@Biotechnology] market capitalization is $77.44M. The market cap for tickers in the [@Biotechnology] industry ranges from $301.75B to $0. The average market capitalization across the [@Biotechnology] industry is $2.17B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACAD’s FA Score shows that 1 FA rating(s) are green whileCTMX’s FA Score has 0 green FA rating(s).

  • ACAD’s FA Score: 1 green, 4 red.
  • CTMX’s FA Score: 0 green, 5 red.
According to our system of comparison, ACAD is a better buy in the long-term than CTMX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACAD’s TA Score shows that 4 TA indicator(s) are bullish while CTMX’s TA Score has 6 bullish TA indicator(s).

  • ACAD’s TA Score: 4 bullish, 6 bearish.
  • CTMX’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, CTMX is a better buy in the short-term than ACAD.

Price Growth

ACAD (@Biotechnology) experienced а +16.20% price change this week, while CTMX (@Biotechnology) price change was +43.93% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -5.06%. For the same industry, the average monthly price growth was +11.12%, and the average quarterly price growth was -13.35%.

Reported Earning Dates

ACAD is expected to report earnings on Jul 30, 2025.

CTMX is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (-5.06% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ACAD($2.82B) has a higher market cap than CTMX($77.4M). ACAD has higher P/E ratio than CTMX: ACAD (10.69) vs CTMX (2.54). CTMX YTD gains are higher at: 5.825 vs. ACAD (-7.738). ACAD has higher annual earnings (EBITDA): 100M vs. CTMX (26.8M). ACAD has more cash in the bank: 756M vs. CTMX (101M). CTMX has less debt than ACAD: CTMX (9.39M) vs ACAD (52M). ACAD has higher revenues than CTMX: ACAD (958M) vs CTMX (138M).
ACADCTMXACAD / CTMX
Capitalization2.82B77.4M3,649%
EBITDA100M26.8M373%
Gain YTD-7.7385.825-133%
P/E Ratio10.692.54420%
Revenue958M138M694%
Total Cash756M101M749%
Total Debt52M9.39M554%
FUNDAMENTALS RATINGS
ACAD vs CTMX: Fundamental Ratings
ACAD
CTMX
OUTLOOK RATING
1..100
178
VALUATION
overvalued / fair valued / undervalued
1..100
58
Fair valued
54
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
2596
PRICE GROWTH RATING
1..100
6236
P/E GROWTH RATING
1..100
10098
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CTMX's Valuation (54) in the Biotechnology industry is in the same range as ACAD (58). This means that CTMX’s stock grew similarly to ACAD’s over the last 12 months.

CTMX's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ACAD (100). This means that CTMX’s stock grew similarly to ACAD’s over the last 12 months.

ACAD's SMR Rating (25) in the Biotechnology industry is significantly better than the same rating for CTMX (96). This means that ACAD’s stock grew significantly faster than CTMX’s over the last 12 months.

CTMX's Price Growth Rating (36) in the Biotechnology industry is in the same range as ACAD (62). This means that CTMX’s stock grew similarly to ACAD’s over the last 12 months.

CTMX's P/E Growth Rating (98) in the Biotechnology industry is in the same range as ACAD (100). This means that CTMX’s stock grew similarly to ACAD’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ACADCTMX
RSI
ODDS (%)
Bearish Trend 2 days ago
69%
Bearish Trend 2 days ago
82%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
72%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
73%
MACD
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
84%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
74%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
73%
Advances
ODDS (%)
Bullish Trend 5 days ago
73%
Bullish Trend 4 days ago
75%
Declines
ODDS (%)
Bearish Trend 11 days ago
72%
Bearish Trend 11 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
77%
Bearish Trend 2 days ago
89%
Aroon
ODDS (%)
Bearish Trend 2 days ago
72%
Bullish Trend 2 days ago
68%
View a ticker or compare two or three
Ad is loading...
ACAD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CTMX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
DAVE152.7344.90
+41.64%
Dave
PSNL5.160.32
+6.61%
Personalis
LEVI17.070.52
+3.14%
Levi Strauss & Co
META598.011.20
+0.20%
Meta Platforms
DHT11.03-0.10
-0.90%
DHT Holdings

ACAD and

Correlation & Price change

A.I.dvisor indicates that over the last year, ACAD has been loosely correlated with XNCR. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if ACAD jumps, then XNCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACAD
1D Price
Change %
ACAD100%
+16.44%
XNCR - ACAD
45%
Loosely correlated
+10.08%
RGNX - ACAD
44%
Loosely correlated
-1.24%
CTMX - ACAD
43%
Loosely correlated
+13.48%
RCKT - ACAD
43%
Loosely correlated
+11.57%
RVMD - ACAD
42%
Loosely correlated
+11.29%
More

CTMX and

Correlation & Price change

A.I.dvisor indicates that over the last year, CTMX has been loosely correlated with ACAD. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if CTMX jumps, then ACAD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CTMX
1D Price
Change %
CTMX100%
+13.48%
ACAD - CTMX
45%
Loosely correlated
+16.44%
MLEC - CTMX
42%
Loosely correlated
-3.39%
XNCR - CTMX
40%
Loosely correlated
+10.08%
PYXS - CTMX
39%
Loosely correlated
+1.87%
CRBU - CTMX
37%
Loosely correlated
+3.95%
More